etavopivat + hydroxyurea

Text: **Etavopivat + hydroxyurea** is a combination treatment under clinical investigation for sickle cell disease. Etavopivat is an oral, selective small molecule activator of erythrocyte pyruvate kinase R (PKR), designed to boost red blood cell function by increasing ATP production and decreasing 2,3-diphosphoglycerate (2,3-DPG) levels. This improves hemoglobin-oxygen affinity and helps prevent sickling of red blood cells, which is crucial in sickle cell disease[2][3][5][7][9]. Hydroxyurea, an established therapy for sickle cell disease, works primarily by increasing fetal hemoglobin (HbF) levels, reducing episodes of vaso-occlusion and hemolysis, and replenishing cellular antioxidants[6][8]. The combination aims to synergistically improve red blood cell health, reduce anemia, and decrease the frequency of vaso-occlusive crises.